What You Should Know:
– Biolinq, a healthcare technology company focused on developing precision multi-analyte biosensors to improve metabolic health raises $100M in Series C financing round led by Alpha Wave Ventures, with participation from several existing investors, including RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital.
– The company will use the funding to support its efforts in obtaining US regulatory approval and prepare for the market launch of its first autonomous intradermal glucose sensor.
Wearable Biosensor Patch
Biolinq’s primary product is a wearable biosensor patch that is applied to the upper forearm and utilizes an array of tiny electrochemical sensors to continuously measure glucose levels just beneath the skin’s surface. The patch also features a color-changing indicator light to provide users with real-time feedback on their glucose excursions. Biolinq emphasizes the ease of use and reliability of its first-generation glucose sensor, which is built on a biosensing platform designed to accommodate future multi-analyte sensing capabilities.
“This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device,” said Rich Yang, CEO. “Our team has spent the last decade developing a biosensor platform designed to inspire healthier living by providing context around a person’s metabolic health.”
